Nitric oxide (NO) activates corpus cavernosum smooth muscle soluble guanylate cyclase (sGC) and increases the synthesis of cGMP that results in smooth muscle relaxation and ultimately, penile erection. To characterize sGC and define the potential synergy between NO and the allosteric activator YC-1 in corpus cavernosum, rat sGC was activated by either sodium nitroprusside (SNP) or YC-1, and YC-1 potentiated the effects of SNP with a 200-fold activation of sGC. Both SNP and YC-1 decreased the K m and increased the V max . ODQ significantly inhibited sGC activated by SNP with IC 50 of 0.5 nM, but did not affect the sGC activated by YC-1 as well as basal sGC activity. SNP and YC-1 synergistically increased intracellular cGMP levels in rabbit corpus cavernosum smooth muscle cell cultures. YC-1 significantly relaxed rabbit cavernosum tissue strips in organ baths with an EC 50 of 8.4 mM. In the presence of L-nitroarginine methyl ester to block endogenous NO production, co-administration of SNP shifted the dose response of YC-1 to the left, showing the synergism of SNP and YC-1 in tissue strips. In view of the clinical efficacy of phosphodiesterase-5 inhibitors, activation of sGC may provide an alternative means for enhancing the activity of neurally derived NO during sexual stimulation in the corpus cavernosum, representing a novel approach for the treatment of erectile dysfunction.
Introduction
Nitric oxide (NO), a key neurotransmitter mediating penile erection, exerts its effects by activating corpus cavernosum smooth muscle soluble guanylate cyclase (sGC). 1,2 sGC is responsible for the enzymatic conversion of GTP to cyclic GMP (cGMP), and the increase of cGMP mediates relaxation of cavernosal smooth muscle leading to penile erection.
The discovery that NO-sGC-cGMP system is one of the major effectors in penile smooth muscle relaxation has led to the development of two classes of agents that increase cGMP levels in cavernosal smooth muscle: (a) agents that inhibit cGMP degradation (phosphodiesterase inhibitors); and (b) agents that elevate cGMP synthesis (sGC activators). The latter class can be divided into NO-dependent and NO-independent sGC activators.
Sildenafil increases cGMP levels by inhibiting phosphodiesterase-5, the enzyme that degrades cGMP. On the other hand, NO or NO donors including nitroglycerine and sodium nitroprusside (SNP) are well-known sGC activators.
A novel type of sGC activators is represented by YC-1. 3 This agent is not an NO donor, but causes activation of sGC especially in the presence of NO. 4, 5 The finding that YC-1 activates sGC by binding to an allosteric site on the enzyme opened the possibility to discover a new class of compounds with a different pharmacological profile in comparison to the NO donors. The goal of this study was to characterize sGC and define the potential synergy between NO and the allosteric activator YC-1 in corpus cavernosum, and to discuss the possibility that the regulation of sGC by activators may represent a new approach for the treatment of erectile dysfunction.
Materials and methods

Chemicals
and SNP (sodium nitroprusside) were purchased from Sigma RBI (St Louis, MO, USA), and GTP obtained from Roche Molecular Biochemicals (Indianapolis, IN, USA). Oligonucleotides were synthesized and purified in-house. Other reagents were obtained from Sigma, otherwise indicated.
sGC expression in human corpus cavernosum
To identify the sGC isoforms expressed in human penile corpus cavernosum, reverse transcriptasepolymerase chain reaction (RT-PCR) analysis was performed. Human penile corpus cavernosum tissues were obtained from Zoion Diagnostics (Shrewsbury, MA, USA). Total RNA was isolated using TRIzol reagent (Life Technologies). Five micrograms of total RNA was reverse-transcribed in a 20 ml reaction mixture containing 500 ng of oligo(dT) 12 -18 , 0.5 mM deoxynucleoside triphosphates, 10 mM dithiothreitol, 5 mM MgCl 2 , 40 units RNase inhibitor in RT reaction buffer and 50 units of SuperScript II RT (Life Technologies) at 42 C for 50 min. PCR reactions were carried out in a 50 ml reaction mixture containing 0.2 mM deoxynucleoside triphosphates, 1.5 mM MgCl 2 , 20 nM of specific primers, cDNA, and two units of Taq DNA polymerase in PCR reaction buffer (Life Technologies). Amplified products were resolved on a 1% agarose gel containing ethidium bromide. The following PCR primer pairs and conditions were used: sGC a 1 subunit (488 bp product), 
Recombinant baculovirus
Rat sGC a 1 -and b 1 -subunits 6, 7 were subcloned into pVL1392 (Invitrogen, Carlsbad, CA, USA) and prepared recombinant baculoviruses encoding the a 1 and the b 1 subunits of sGC by the standard protocol. 8 
Insect cell culture
Sf9 or High5 cells were grown in suspension culture in flasks or roller bottles at 28 C. SF900II serum-free medium (Life Technologies) was used for culture without any supplements.
sGC expression
The cells were grown to 2610 6 cells=ml and then infected with a mixture of the virus stocks for the a 1 -and b 1 -subunits for protein production. We found that the best expression of sGC activity was achieved by a multiplicity of infection of 0.1 pfu each subunit=cell and the three days incubation at 28 C. Cells were harvested and stored at 7 80 C. The cell pellets were thawed on ice and were homogenized with Tekmer Sonic Disruptor (Cincinnati, OH, USA) in 5 vol of 20 mM Tris -HCl (pH 7.6) containing 1 mM EDTA, 5 mM dithiothreitol, 90 mM NaCl, 10% glycerol, and 1 Protease Inhibitor Cocktail Tablet per every 50 ml (Roche Molecular Biochemicals, Indianapolis, IN, USA). The homogenate was centrifuged at 50000 g for 30 min, and the supernatant was used for GC purification. Purification was performed from 3 l culture of High5 cells as described previously, 9 and the purified preparation was aliquoted and stored at 7 80 C until use.
GC enzyme assay
GC enzyme activity assay was performed as described previously with modifications to allow us to assay large number of samples at the same time. 7 Assay mixtures contained 50 mM Tris -HCl (pH 7.6), 4 mM MgCl 2 , 5 mM creatin phosphate, 0.5 mM IBMX, 4 units=ml creatin kinase and 1 mM GTP in a volume of 100 ml in 96-well plate (Thermowell) (Costar, Corning, NY, USA). The incubation was carried out for 10 min at 37 C followed by 95 C for 2 min to terminate the reaction using GeneAmp PCR System 9600 (PE Biosystems, Foster City, CA, USA). Produced cGMP from GTP was quantified by enzyme immunoassay (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
cGMP measurement in smooth muscle cell culture
Corpus cavernosal smooth muscle tissues were prepared from adult male New Zealand white rabbits (Covance Research Production, Kalamazoo, MI, USA). Explant cavernosal tissues were placed in small petri dishes in Dulbecco's Modified Eagle Medium containing 10% fetal bovine serum, antibiotics, and amphotercin B. The explants were kept undisturbed for 3 -4 days in 37 C 5% CO 2 incubator. Smooth muscle cells migrated out from the tissues underwent proliferation within 7 days. The explants were removed and the medium was changed every 3 days. Once confluent, cells were detached with trypsin -EDTA and sub-cultured at a density of 0.5610 4 cells=well in 24-well culture plates. All experiments were performed in cavernosum cells that had been grown for 48 h ( > 90% confluent).
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The culture medium was changed and washed with Hank's BSS solution three times immediately before each experiment. The cells were incubated with pharmacological agents with or without 100 mM IBMX prepared in Hank's BSS for 10 min. Cells were lysed with 0.5% (w=v) dodecyl triammonium bromide in 50 mM sodium acetate buffer (pH 5.8). Total cellular cGMP levels were determined using enzyme immunoassay (Amersham Pharmacia Biotech) after acetlylation of cGMP.
Organ bath studies
Rabbit corpus cavernosum strips were obtained from euthanized New Zealand White rabbits (Covance Research Production, Denver, PA, USA), weighing 3.5 -4.0 kg. The two corpus cavernosum strips were dissected from the tunica albugenea and each was longitudinally cut into two to three strip preparations. The strips were mounted in an organ bath (10 ml) containing Kreb-Henseleit buffer (Sigma, St Louis, MO, USA) with 2.5 mM CaCl 2 , 25mM NaHCO 3 and 4 mM DL-propranolol, pH 7.4 at 37 C, which were aerated with 95% O 2 and 5% CO 2 . 10 The strips were equilibrated for 90 min with a resting tension of 2 g. Isometric tension of muscle tissue was measured using a force-displacement transducer (FT-202, Kent Scientific, Litchfield, CT, USA) and recorded on a Powerlab 800 (AD Instruments, Castle Hill, Australia) and calculated by Prism (GraphPad Software, San Diego, CA, USA). EC 50 of phenylephrine-induced contraction was determined by cumulatively adding phenylephrine (1610 78 to 3610 74 M) to the tissue bath. The strips were washed, reequilibrated and stretched with tension of 2 g for 90 min. The strips were pre-contracted by EC 50 concentration of phenylephrine for 15 min. Drugs were cumulatively added from low to high to the chamber with 7 min intervals. Relaxation response was expressed as percentage of total tone induced by the addition of EC 50 of phenylephrine. All data were expressed as means AE s.e.m.
Results
To characterize sGC expressed in human corpus cavernosum, RNA was extracted from tissue samples obtained from eight patients and RT-PCR was performed. As shown in Figure 1 , specific amplification products encoding the a 1 and b 1 subunits were detected after 30 cycles of PCR. Very weak products encoding a 2 subunits were detected from four patients, but none of the b 2 subunit products were detected after 30 cycles. Although a 2 and b 2 subunits were detected after 45 cycles of PCR (data not shown), we conclude that the main isoform of sGC expressed in human corpus cavernosum is a 1 =b 1 .
Based on the results above, we expressed a 1 =b 1 isoform of rat sGC in baculovirus system, and purified it to homogeneity. The purified rat sGC was highly activated by either SNP or YC-1 ( Figure  2 ). SNP showed a concentration-dependent activation of sGC with a maximal effect of 50-fold activation at 10 -100 mM and an EC 50 value of 2 mM (Figure 2A ). YC-1 also activated sGC with an effect of 50-fold activation at 100 mM ( Figure 2B) . The activation by YC-1 did not reach maximum at 100 mM, which is the highest concentration tested because of the solubility of YC-1. Interestingly, YC-1 and SNP showed synergistic effects over the range of the dose tested with a maximal activation of sGC by 10 mM SNP and 100 mM YC-1 of around 200-fold activation and one magnitude shift of EC 50 to lower concentrations (Figure 2A and B) .
Effect of SNP and=or YC-1 on the kinetic properties of sGC was examined. Ten micromoles of SNP (maximum effect of activation, see Figure 2 ) increased V max from 1.19 mmol=min=mg to 13.3 mmol= min=mg (11-fold increase), and lowered K m from 446 mM to 130 mM (3.4-fold decrease). Also, 100 mM YC-1 (maximum effect of activation, see Figure 2 ) increased V max from 1.19 mmol=min=mg to 16.2 mmol=min=mg (14-fold increase), and lowered K m from 446 mM to 239 mM (1.9-fold decrease, Figure  3 ). When 10 mM SNP and 100 mM YC-1 were combined, a 30-fold increase of the V max and a 14-fold decrease of the K m were observed, indicating Figure 1 sGC expression in human corpus cavernosum. Total RNA from eight (number 1 to number 8) human penile corpus cavernosum tissues was isolated and ran RT-PCR as described in Materials and methods using the primer pairs of a 1 subunit (488 bp product), a 2 subunit (392 bp product), b 1 subunit (846 bp product) and b 2 subunit (460 bp product).
Activation of guanylate cyclase causes relaxation of cavernosal smooth muscle M Nakane et al that the conformational changes brought about by NO and by YC-1 are synergistic. This result also supports the proposal that YC-1 binding site would be different from NO binding site (the heme domain of sGC, 5 and YC-1 is an allosteric activator of sGC.
ODQ has been reported to be a potent inhibitor of NO-activated sGC. 11,12 ODQ binds to sGC in an NOcompetitive manner and inhibits NO-stimulated activity by oxidizing the ferrous heme in the first complex to a five liganded ferric intermediate. This prevents both binding and activation by NO, leaving basal activity unchanged. 12, 13 We tested the effect of ODQ on sGC activated by SNP and YC-1 (Figure 4) . ODQ significantly inhibited sGC activated by 10 mM SNP with IC 50 of 0.5 nM, but did not affect the sGC activated by 100 mM YC-1 as well as basal sGC activity, indicating that YC-1 binds to sGC at a different site from the heme (NO binding site).
Having established in biochemical characteristics of sGC activation, we wanted to characterize this activity in smooth muscle cells in vitro. We prepared a primary culture of rabbit corpus cavernosum smooth muscle cells and observed the effect of SNP and=or YC-1 on the intracellular concentration of cGMP. YC-1 increased cGMP level dosedependently ( Figure 5 ). In the presence of 1 mM (sub-optimal concentration, data not shown) SNP, YC-1 drastically increased cGMP, much more than YC-1 alone, indicating that SNP and YC-1 synergistically increased intracellular cGMP levels in rabbit corpus cavernosum smooth muscle cells.
We examined the ability of sGC activators to relax phenylephrine pre-contracted cavernosum tissue strips in vitro. YC-1 significantly relaxed cavernosum tissue strips in a dose-dependent manner with an EC 50 of 8.4 mM ( Figure 6A ). When the strips were pre-treated with 100 mM of nitric oxide synthase inhibitor, L-NAME to avoid the endogenous NO effect, YC-1 induced a concentration-dependent relaxation, but less potently (EC 50 ¼ 50 mM) ( Figure  6B ). This indicates that endogenous NO significantly contributes to the relaxation caused by YC-1 Figure 6B ). EC 50 shifted from 50 mM to 3 mM with 1 mM SNP.
Discussion
In this study, YC-1 synergistically activates sGC in the presence of sub-maximal concentration of NO, increases intracellular cGMP levels in cavernosal smooth muscle cells, and causes relaxation of corpus cavernosum.
YC-1 has been identified as an inhibitor of platelet aggregation that led to an increase of intracellular cGMP. 3, 14 Soon after the finding the pharmacological effect of YC-1 on platelets, YC-1 was found to be a modulator of sGC activity. 15 Interestingly, YC-1 highly potentiates the stimulatory effect of submaximally activating NO (Figure 1 ). In the presence of YC-1, the NO concentrationresponse curve is shifted to the left, indicating that YC-1 sensitized sGC towards NO.
YC-1 binds to sGC at a different site from the heme. 5, 16 This is evidenced by studies in which YC-1 can act as an allosteric activator in the absence of NO and lead to even more activation in the presence Figure 4 ODQ inhibits NO-stimulated sGC activity, but does not inhibit YC-1-stimulated and basal sGC activity. sGC activity was measured in the presence of increasing concentration of ODQ in the absence or presence of 10 mM SNP or 100 mM YC-1. Results are the means AE s.e.m. from three independent experiments performed in duplicate and normalized with the activity without ODQ as 100%. **P < 0.05, ***P < 0.01 vs basal. Figure 5 SNP and YC-1 synergistically increase intracellular cyclic GMP in cultured smooth muscle cells from corpus cavernosum. Rabbit corpus cavernosum smooth muscle tissues were prepared as described in Materials and methods. The cells were incubated with the increasing concentration of YC-1 with or without 1 mM SNP in the presence of 100 mM IBMX for 10 min. Total cellular cGMP levels were determined using enzyme immunoassay. Results are the means AE s.e.m.: **P < 0.05, ***P < 0.01 vs vehicle. Figure 6 SNP potentiates relaxation by YC-1 with pretreatment of L-NAME. Rabbit corpus cavernosum strips were dissected and prepared as described in Materials and methods. (A) The strips were pre-contracted by EC 50 concentration of phenylephrine for 15 min and YC-1 was cumulatively added from low to high to the chamber with 7 min intervals. (B) The strips were pre-contracted by EC 50 concentration of phenylephrine in the presence of 100 mM L-NAME for 15 min and YC-1 in the absence or presence of 0.1 mM or 1 mM SNP were cumulatively added from low to high to the chamber with 7 min intervals. Relaxation response was expressed as percentage of total tone induced by the addition of EC 50 of phenylephrine and the results were expressed as means AE s.e.m. **P < 0.05, ***P < 0.01 vs control.
Activation of guanylate cyclase causes relaxation of cavernosal smooth muscle M Nakane et al of NO, decreasing the K m for GTP and increasing the V max of cGMP formation (Figure 2 ). This site has recently been mapped using a photoaffinity labeling technique to the a-subunit cysteines 238 and 243 of human sGC. 17 This report does not agree with earlier work that suggested that cysteine 541 of the bsubunit was key for YC-1 interaction, 18 and the binding of YC-1 to the sGC heme-binding domain leading to conformational changes. 19 This may reflect the nature of the conformational change as well as the initial binding of YC-1.
For sGC to possess two different allosteric activators is fortuitous therapeutically. sGC activator binding to the allosteric non-heme site that in it has little effect on increasing the basal activity, but in the presence of NO, can greatly amplify the effects of NO, would be a good candidate for male erectile dysfunction. YC-1 activates sGC through a pathway that does not involve the interaction with the heme moiety and cause a pronounced sensitization of the enzyme for stimulation by NO. 5 YC-1 induced a concentration-dependent relaxation in rabbit aortic rings pre-contracted with phenylephrine by increasing intracellular cGMP levels. 20 We also observed that YC-1 synergistically increased intracellular cGMP levels in rabbit cavernosal smooth muscle cells (Figure 4 ) and induced a relaxation in rabbit corpus cavernosum strips and the potencies shifted to the left in the presence of NO donor, SNP ( Figure 5 ). The synergistic responses to NO-donor and YC-1 in cultured cavernosal smooth muscle cells and isolated corpus cavernosum strips apparently reflect the direct synergistic action of YC-1 and NO on the sGC.
In sGC enzyme assay, we observed that ODQ did not block the activation of sGC by YC-1 (Figure 3) . However, YC-1 induced a concentration-dependent relaxation in rat aortic rings pre-contracted with phenylephrine, and the relaxant effects of YC-1 were reversed by ODQ and potentiated by NO donor. 21 The endogenous NO in tissue preparations produced by nitric oxide synthase can explain this difference of ODQ effect. In pre-constricted rat aortic rings, YC-1 produced a concentration-dependent relaxation, and the concentration -response curve was shifted towards the right, to higher concentrations of YC-1 when the aortas were pre-treated with nitric oxide synthase inhibitor, L-NAME. 22 In view of the clinical efficacy of phosphodiesterase-5 inhibitors, agents that activate sGC may provide a means for enhancing the activity of NO in the corpus cavernosum, representing a novel approach for the treatment of erectile dysfunction. Pharmacological studies in vivo support this concept. Systemic injections of YC-1 facilitated penile erections in rats, indicating that the activation of sGC via this allosteric site in the enzyme can lead to penile erection in mammals (manuscript in preparation). Although YC-1 has already been proposed for the treatment of cardiovascular and thrombotic disorders, YC-1 as well as activators of sGC can also be beneficial for the treatment of male erectile dysfunction.
